Kuros Biosciences, a Swiss bone healing technology company, reported total product sales of $43.4 million in the first quarter of 2026, up 51% from $28.8 million in Q1 2025. Direct MagnetOs product sales rose 51% to $42.9 million. The company achieved group EBITDA of $2.9 million, compared to $2.0 million in Q1 2025. Adjusted EBITDA reached $5.7 million, representing a 13.1% margin. Cash and cash equivalents totalled $15.7 million, down from $19.8 million at year-end 2025, reflecting investments in production capacity expansion. Kuros saw strong growth in minimally invasive surgery procedures and extremities applications. A retrospective study published in Spine Open reported an 87% fusion rate for MagnetOs Easypack Putty in high-risk posterior lumbar fusion patients. The company's new US manufacturing facility in Alpharetta, Georgia, remains on track for production in the second half of 2026.

Kuros Biosciences, a Swiss musculoskeletal care company, is highlighted among European growth stocks with high insider ownership. The firm focuses on commercialising biologic technologies across the United States and European Union, with a market capitalisation of CHF898.68 million. The company generates revenue through its medical devices segment, which brought in $146.06 million. Kuros is amongst 213 fast-growing European companies identified in a recent screener, selected during a period when the STOXX Europe 600 Index rose 3.92%. The analysis comes as investor sentiment improves amid hopes of a shorter Middle East conflict and robust gains in major indices including Germany's DAX and the UK's FTSE 100. High insider ownership typically signals strong confidence from company leadership.

Kuros Biosciences, a leader in bone healing technologies, reported 72% year-over-year sales growth, reaching $146.1 million for 2025, up from $85.2 million in 2024. Direct MagnetOs sales increased 71% to $143.9 million. The company achieved its first-ever net profit of $2.6 million, compared to a $4.8 million loss in 2024. Group EBITDA reached $12.4 million, whilst adjusted EBITDA hit $19.6 million with a 13.4% margin. Cash and cash equivalents stood at $19.8 million. For 2026, Kuros expects at least 35% sales growth with an adjusted EBITDA margin around 14%. By 2028, the company anticipates sales between $300 million and $330 million with an adjusted EBITDA margin of at least 20%.